Phase I/II Randomized Trial of Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC-HIV (vCP1452) Prime/LIPO-5 Boost in Healthy, HIV-1-Uninfected Adult Participants

Finding an effective human immunodeficiency virus type 1 (HIV-1) vaccine remains a major global health priority. In a phase I/II, placebo-controlled trial, healthy, HIV-1-negative adults were randomized to receive one of 5 vaccine regimens: LIPO-5 (combination of 5 lipopeptides) alone (250 μg), ALVA...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Clin Vaccine Immunol
Main Authors: Frey, Sharon E., Peiperl, Laurence, McElrath, M. Juliana, Kalams, Spyros, Goepfert, Paul A., Keefer, Michael C., Baden, Lindsey R., Lally, Michelle A., Mayer, Kenneth, Blattner, William A., Harro, Clayton D., Hammer, Scott M., Gorse, Geoffrey J., Hural, John, Tomaras, Georgia D., Levy, Yves, Gilbert, Peter, deCamp, Allan, Russell, Nina D., Elizaga, Marnie, Allen, Mary, Corey, Lawrence
Formato: Artigo
Idioma:Inglês
Publicado em: American Society for Microbiology 2014
Assuntos:
Vaccines
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4248765/
https://ncbi.nlm.nih.gov/pubmed/25253665
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/CVI.00450-14
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados